Review finds better cardiovascular outcomes after bariatric surgery than drug treatment

What happened

A systematic review pooled 15 controlled studies that compared metabolic and bariatric surgery with medication in people living with both obesity and type 2 diabetes. The researchers looked beyond weight loss. Their outcomes included major cardiovascular events, blood pressure, A1C, blood glucose, cholesterol and triglycerides.

Across the studies, surgery was associated with fewer major cardiovascular events and larger improvements in most of the measured risk factors. For the five-year cardiovascular outcome, the pooled odds ratio was 0.66, with a 95% confidence interval from 0.59 to 0.73. That is a relative comparison between the treatment groups. The abstract does not provide the event counts needed to show the absolute difference.

The timing varied by outcome. The review reported larger early changes after surgery in A1C, total cholesterol and LDL cholesterol. Differences in triglycerides and HDL cholesterol were seen through two years. Blood-pressure differences appeared later, while the fasting-glucose comparison extended through year five. The size of the findings varied with follow-up duration, BMI group and the medicines included in the comparison.

What it means

For someone weighing surgery against medication, this review supports looking at more than the number on the scale. Diabetes control and cardiovascular risk are part of the same decision. In the studies the authors could combine, surgery was associated with better results across several of those outcomes.

The paper also adds a longer view to the discussion. Some differences did not appear in the same time window, and the cardiovascular-event finding was reported at five years. A useful treatment conversation should therefore cover the likely durability of each option, not only the first few months of weight change.

What it does not mean

This meta-analysis does not prove that surgery is the best choice for every person. It combines different studies, follow-up periods, drug classes and BMI groups. The PubMed abstract does not say how many included studies were randomized, so treatment selection and other differences between the groups may have affected the pooled result.

The review also cannot answer every practical question from its abstract. It does not give absolute cardiovascular-event rates or a single comparison of surgical complications, medication adverse effects, discontinuation and reoperation. Its database search ended on April 12, 2025, so it may not represent head-to-head outcomes against every newer obesity medicine or regimen now in use.